CytomX Therapeutics (CTMX) Issues Strategic Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/10/2026
- US stocks close down as oil spikes 12%, job market weakens
- U.S. nonfarm payroll employment unexpectedly falls in February
- Oracle stock falls on report of scrapped Texas data center plans
- Kuwait cuts oil output as storage fills up
- Boeing reportedly nearing 500-aircraft deal with China ahead of Trump visit
- After-hours movers: Marvell, Samsara, GAP, Cooper Cos.
- After-hours movers: Broadcom, StubHub, Cracker Barrel, Grocery Outlet, Veeva Systems and more
- After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
- After-hours movers: MongoDB, Credo, SoFi Technologies and more
- After-hours movers: Dell, Block, CoreWeave, Autodesk, MARA and more
CytomX Therapeutics Provides Strategic Update
July 13, 2022 4:05 PM UTC- Company to focus internal efforts on wholly-owned next-generation conditionally activated therapeutics, including IFN alpha-2b cytokine and EpCAM-directed ADC, INDs planned for 2023 -
- Partnered clinical-stage programs continue to advance: Phase 2 programs, BMS-986249 (anti-CTLA-4) and CX-2029 (anti-CD71 ADC); and Phase 1 programs, CX-904 (EGFRxCD3 bispecific) and BMS-986288 (anti-CTLA-4) -
- Company restructuring to realign capital resources and extend cash runway to 2025 -
- Company to host conference call and webcast today at 6:00 pm ET / 3:00 pm PT -
SOUTH SAN FRANCISCO, Calif., July 13,... More
